Our Pipeline
Advancing a multi-asset pipeline of high-impact therapeutic solutions
Our pipeline is comprised of innovative therapeutic product candidates we believe have the potential for value creation using our partnership-enabled business model.
Target Disease
Program
Target Population
Preclinical
Clinical Feasibility
Clinical Pivotal
Hypertensive Heart Disease
$17 Billion Annual Global Opportunity
Atrioventricular Interval Modulation(AVIM) Therapy
Preclinical
Clinical Feasibility
Clinical Pivotal
Hypertension (HTN) & Pacemaker
BACKBEAT Global Pivotal Study Enrolling & FDA Breakthrough
HTN with Increased CV Risk
(Non-pacemaker indicated)
(Non-pacemaker indicated)
FDA Breakthrough
HTN & Heart Failure
FDA Breakthrough
AVIM/Cardiac Neuromodulation Therapy may have additional clinical application in advanced heart failure.
Atherosclerotic Artery Disease
$10 Billion Annual Global Opportunity
Virtue® Sirolimus AngioInfusion™ Balloon (SAB)
Preclinical
Clinical Feasibility
Clinical Pivotal
Coronary In-Stent Restenosis (ISR)
IDE Approved & FDA Breakthough
Coronary Small Vessel (SV)
FDA Breakthough
Below-the-Knee (BTK)
FDA Breakthough
Other Coronary & Peripheral Indications
SirolimusEFR™ may have potential clinical application in a variety of non-vascular indications.
Our flagship product candidates, AVIM Therapy and Virtue SAB, exemplify key criteria that characterize innovations optimized for strategic partnerships:
Target mature therapeutic device markets with significant unmet needs
Provide high-impact procedure-based solutions with rapid adoption potential
Offer strategic and financial benefits to a commercial partner and Orchestra BioMed
* Plan to leverage existing coronary in-stent restenosis (ISR) data to support potential Pivotal Study; Virtue SAB has received Breakthrough Device Designation for:
- The balloon dilation of the stenotic portion (up to 26 mm in length) of a stented coronary artery that is 2.25 to 4.0 mm in diameter, for the purpose of improving lumen diameter.
- The balloon dilation of the de novo stenotic portion (up to 28 mm in lesion length) of a native coronary artery of 2.0 mm to 2.5 mm in diameter (small coronary arteries), for the purpose of improving lumen diameter.
- The balloon dilation of the stenotic portion (up to 18 mm in length) of an infrapopliteal artery (P-3 segment or distal, below the knee) with a reference vessel diameter (RVD) of 2.25 to 4.0 mm, for the purpose of improving lumen diameter.
Virtue® SAB is investigational and not commercially approved.
AVIM therapy is investigational and not commercially approved.